Evercore ISI analyst Elizabeth Anderson raised the price target on Charles River (CRL) to $200 from $190, maintaining an Outperform rating. Survey work suggests positive outlook for preclinical CROs, stable demand for discovery and toxicology services into 2025 and 2026. Source: TheFly. For more information on CRL, visit TipRanks.

Read more at Yahoo Finance: Charles River price target raised to $200 from $190 at Evercore ISI